
Veru VERU
€ 2.18
0.8%
Quartalsbericht 2025-Q4
hinzugefügt 11.02.2026
Veru Operativer Cashflow 2011-2026 | VERU
Operativer Cashflow Jährlich Veru
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.7 M | -88 M | -47.5 M | -15.6 M | -1.93 M | -5.49 M | -11.5 M | 983 K | - | - | - | 11.8 M | 10.4 M | 6.97 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 11.8 M | -88 M | -14.7 M |
Operativer Cashflow Vierteljährlich Veru
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.17 M | - | - | - | -11.3 M | - | - | - | -6.02 M | - | - | - | -34.5 M | -26.6 M | - | - | -8.66 M | -14.8 M | -1.93 M | - | 659 K | -1.59 M | -4.93 M | 659 K | -2.51 M | -4.53 M | -4 M | -2.51 M | -1.51 M | -8.73 M | -4.18 M | -1.51 M | 297 K | 405 K | -1.06 M | 297 K | 1.17 M | - | - | - | - | - | - | - | - | - | - | - | 1.18 M | - | 4.99 M | - | 1.02 M | 9.03 M | 5.05 M | 1.02 M | 1.86 M | 4.61 M | 2.54 M | 1.86 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 9.03 M | -34.5 M | -3.16 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
-166 M | $ 1.05 | -3.24 % | $ 113 M | ||
|
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B | ||
|
Evolus
EOLS
|
-42.3 M | $ 5.74 | 2.59 % | $ 370 M | ||
|
China Pharma Holdings
CPHI
|
-466 K | $ 0.54 | -7.57 % | $ 9.43 M | ||
|
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.54 | -3.54 % | $ 49.8 M | ||
|
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B | ||
|
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M | ||
|
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | ||
|
Harrow Health
HROW
|
43.9 M | $ 36.19 | -7.73 % | $ 1.33 B | ||
|
Aurora Cannabis
ACB
|
-211 M | $ 3.51 | -3.84 % | $ 86.3 M | ||
|
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | ||
|
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | ||
|
Emergent BioSolutions
EBS
|
-206 M | $ 8.49 | -3.19 % | $ 435 M | ||
|
Assertio Holdings
ASRT
|
49.6 M | $ 11.96 | -0.89 % | $ 850 M | ||
|
Bausch Health Companies
BHC
|
1.03 B | $ 5.56 | -1.24 % | $ 2.03 B | ||
|
Organogenesis Holdings
ORGO
|
14.2 M | $ 2.89 | 0.52 % | $ 381 M | ||
|
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.46 | 4.68 % | $ 402 M | ||
|
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | ||
|
Sundial Growers
SNDL
|
-155 M | $ 1.52 | -1.3 % | $ 3.37 M | ||
|
Perrigo Company plc
PRGO
|
238 M | $ 11.22 | -4.06 % | $ 1.55 B | ||
|
TherapeuticsMD
TXMD
|
-159 M | $ 2.24 | 3.86 % | $ 23.4 M | ||
|
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | ||
|
Viatris
VTRS
|
2.9 B | $ 14.58 | -0.92 % | $ 17.5 B | ||
|
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
-353 K | $ 0.69 | -10.34 % | $ 2.98 M | ||
|
Rockwell Medical
RMTI
|
-9.41 M | $ 0.88 | -0.91 % | $ 20.5 M | ||
|
Pacira BioSciences
PCRX
|
189 M | $ 22.78 | -0.35 % | $ 1.05 B | ||
|
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.45 | -6.81 % | $ 134 M | ||
|
SCYNEXIS
SCYX
|
-5.28 M | $ 0.76 | -2.49 % | $ 37.9 M | ||
|
Solid Biosciences
SLDB
|
-100 M | $ 5.62 | -8.55 % | $ 229 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.66 | -5.0 % | $ 3.3 M | ||
|
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
7.91 M | $ 7.07 | -3.15 % | $ 4.37 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M |